VEGF is a critical driver of ocular neovascularization under disease conditions. Current therapeutic strategies rely on intraocular delivery of
VEGF-antagonizing
reagents, which results in sustained suppression of pathogenic vascularization. Although significant advancement has been achieved in
VEGF antagonism, substantial adverse effects have been reported in retrospective clinical studies. To study mechanisms for
VEGF antagonism-associated adverse effects in visual system, we intravitreally delivered recombinant adeno-associated virus-mediated expression of soluble Fms-related
tyrosine kinase-1 (rAAV.sFLT-1), the extracellular domain of
VEGF receptor, and analyzed the morphology and functions of
retinal tissue. Here, we confirmed that intraocular
VEGF antagonism induced
retinal degeneration and
gliosis. The functional deficit in
retinal response to visual stimulation was also demonstrated in rAAV.sFLT-1-treated eyes by electroretinogram. Moreover, high-throughput
RNA sequencing analysis suggests that
VEGF antagonism activates
retinal degeneration,
inflammation, and other adverse effects. Taken together, our findings have shed light on pathogenic mechanisms for
VEGF antagonism-associated adverse effects and potential therapeutic targets.-Xiao, M., Liu, Y., Wang, L., Liang, J., Wang, T., Zhai, Y., Wang, Y., Liu, S., Liu, W., Luo, X., Wang, F., Sun, X. Intraocular
VEGF deprivation induces degeneration and fibrogenic response in retina.